Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648636 | 0.87 | C5AR1 (0.51) | C5AR1PTGESALOX5TSHRALDH1A1 | |
| SCHEMBL1912886 | 0.87 | C5AR1 (0.45) | C5AR1TSHRALDH1A1MAPK1HPGD | |
| SCHEMBL651171 | 0.84 | C5AR1 (0.42) | C5AR1CXCR3ALDH1A1MAPK1MAPT | |
| SCHEMBL5137558 | 0.83 | C5AR1 (0.49) | C5AR1CXCR3PTGESALOX5TSHR | |
| SCHEMBL647753 | 0.83 | C5AR1 (0.49) | C5AR1PTGESALOX5TSHRALDH1A1 | |
| SCHEMBL648187 | 0.83 | C5AR1 (0.46) | C5AR1CXCR3ALDH1A1MAPK1GAA | |
| SCHEMBL647608 | 0.82 | C5AR1 (0.48) | C5AR1PTGESALOX5ALDH1A1MAPT | |
| SCHEMBL650057 | 0.82 | C5AR1 (0.51) | C5AR1TSHRALDH1A1MAPK1GAA | |
| SCHEMBL648911 | 0.82 | PTGES (0.46) | C5AR1PTGESALOX5TSHRALDH1A1 | |
| SCHEMBL1913084 | 0.82 | C5AR1 (0.51) | C5AR1PTGESALOX5TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-22 | — | — | US | claimed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885CXCR3 158/4885PTGES 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.